bioRxiv · 10.1101/2023.11.06.565807
Myospreader improves gene editing in skeletal muscle by myonuclear propagation
Abstract
Successful CRISPR/Cas9-based gene editing in skeletal muscle is dependent on efficient propagation of Cas9 to all myonuclei in the myofiber. However, nuclear-targeted gene therapy cargos are strongly restricted to their myonuclear domain of origin. By screening nuclear localization signals and nuclear export signals, we identify "Myospreader", a combination of short peptide sequences that promotes myonuclear propagation. Appending Myospreader to Cas9 enhances protein stability and myonuclear propagation in myoblasts and myofibers. AAV-delivered Myospreader dCas9 better inhibits transcription of toxic RNA in a myotonic dystrophy mouse model. Furthermore, Myospreader Cas9 achieves higher rates of gene editing in CRISPR reporter and Duchenne muscular dystrophy mouse models. Myospreader reveals design principles relevant to all nuclear-targeted gene therapies and highlights the importance of the spatial dimension in therapeutic development.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Poukalov, K., Valero, M. C., Muscato, D., Adams, L., Chun, H., Lee, Y. i. T., Andrade, N., Zeier, Z., Sweeney, H. L., Wang, E. T.. 2023-11-06. Myospreader improves gene editing in skeletal muscle by myonuclear propagation. https://doi.org/10.1101/2023.11.06.565807
Cite the original work for its findings. Save a collection to share your selection of sources.